Collaboration aims to uncover biomarkers for prostate cancer

04/23/2013 | GenomeWeb Daily News (free registration)

The Ontario Institute for Cancer Research has agreed to work with Johnson & Johnson unit Janssen on clinical trials that aim to develop new biomarkers for detecting hormone-resistant prostate cancer and predicting therapeutic response. The project will leverage OICR's background in molecular imaging, genomics and circulating tumor cells. As part of the project, researchers will test new imaging agents in tumor evaluation and treatment response assessment.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC